FDCC
PLRX icon

Foster Dykema Cabot & Co’s Pliant Therapeutics PLRX Stock Holding History

Foster Dykema Cabot & Co’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-88
Closed -$2K – 373
2023
Q2 		$2K Buy
+88
New +$2.08K ﹤0.01% 357

Other funds holding PLRX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Foster Dykema Cabot & Co's PLRX Position: Q3 2023 in Review

Foster Dykema Cabot & Co sold out of Pliant Therapeutics (PLRX) in Q3 2023, closing a stake of 88 shares — an estimated $2K sold.

Foster Dykema Cabot & Co first reported a position in PLRX in Q2 2023 and held it in 1 quarter. The position peaked at $2K in Q2 2023. 136 funds tracked by Wall St. Rank hold PLRX as of Q3 2023.

  • Foster Dykema Cabot & Co reported no remaining Pliant Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Foster Dykema Cabot & Co sold 88 Pliant Therapeutics shares in Q3 2023, an estimated $2K.
  • Foster Dykema Cabot & Co first reported a position in Pliant Therapeutics in Q2 2023 and held it in 1 quarter.
  • Foster Dykema Cabot & Co's Pliant Therapeutics position peaked at $2K in Q2 2023.
  • 136 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2023.

Based on Foster Dykema Cabot & Co's 13F filing for Q3 2023, filed 14 Nov 2023.